Loading…
TZT-1027 Elucidates Antitumor Activity through Direct Cytotoxicity and Selective Blockade of Blood Supply
Background: TZT-1027 is a newly developed antitumor agent derived from dolastatin 10. Materials and Methods: The in vitro activity of TZT-1027 on MCF-7 and R-27 cells was evaluated by MTT assay. TZT-1027 1 mg/kg/week was administered i.v. for 4 weeks into nude mice bearing MCF-7 and R-27. Subsequent...
Saved in:
| Published in: | Anticancer research 2004-07, Vol.24 (4), p.2201-2208 |
|---|---|
| Main Authors: | , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | |
|---|---|
| cites | |
| container_end_page | 2208 |
| container_issue | 4 |
| container_start_page | 2201 |
| container_title | Anticancer research |
| container_volume | 24 |
| creator | HASHIGUCHI, Naoko KUBOTA, Tetsuro KOBAYASHI, Motohiro KOH, Jun-Ichi YAMADA, Yoshinori SAIKAWA, Yoshiro OTANI, Yoshihide WATANABE, Masahiko KUMAI, Koichiro KITAJIMA, Masaki WATANABE, Jun-Ichi |
| description | Background: TZT-1027 is a newly developed antitumor agent derived from dolastatin 10. Materials and Methods: The in vitro
activity of TZT-1027 on MCF-7 and R-27 cells was evaluated by MTT assay. TZT-1027 1 mg/kg/week was administered i.v. for 4
weeks into nude mice bearing MCF-7 and R-27. Subsequently, primary cultured cells from xenografts were also used for CD-DST.
Two mg of TZT-1027 or 40 mg docetaxel per kg were injected i.v. into nude mice bearing R-27. 0.2% Evans blue was injected
to assess the blood flow. Results: TZT-1027 suppressed the in vitro growth of MCF-7 cells, while R-27 cells were resistant
to TZT-1027, although its in vivo antitumor activity was remarkable. TZT-1027 blockaded R-27 tumor blood flow immediately
after injection; blood flow was not affected by docetaxel. Conclusion: TZT-1027 exerts its antitumor activity through direct
cytotoxicity against MCF-7 cells and through selective blockade of tumor blood flow against R-27 cells. |
| format | article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_66820031</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>66820031</sourcerecordid><originalsourceid>FETCH-LOGICAL-h267t-2ce1a7cbf1743b1d64fa920fa7b08172a1567d2095c10768e6eabd0b72608b4b3</originalsourceid><addsrcrecordid>eNpN0L1OwzAUBWALgWgpvALyAlukazuxk7GUX6kSA2VhiRzHaQxOHGIHyNuTiiJ1ulc6n85wjtCciIxEImFwjOZAE4gEQDJDZ96_A3CepewUzUjCGBBO5shs3jYRASrwnR2UKWXQHi_bYMLQuB4vVTBfJow41L0btjW-Nb1WAa_G4IL7MWqXybbEL9rqndX4xjr1IUuNXbX73ZQNXWfHc3RSSev1xf4u0Ov93Wb1GK2fH55Wy3VUUy5CRJUmUqiiIiJmBSl5XMmMQiVFASkRVJKEi5JCligCgqeaa1mUUAjKIS3igi3Q9V9v17vPQfuQN8Yrba1stRt8znlKARiZ4OUeDkWjy7zrTSP7Mf8fZwJXeyC9krbqZauMP3BZKtL0wNVmW39PA-W-kdZOtSyXPY3zOKcUCPsFJtl61Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>66820031</pqid></control><display><type>article</type><title>TZT-1027 Elucidates Antitumor Activity through Direct Cytotoxicity and Selective Blockade of Blood Supply</title><source>Free E-Journal (出版社公開部分のみ）</source><creator>HASHIGUCHI, Naoko ; KUBOTA, Tetsuro ; KOBAYASHI, Motohiro ; KOH, Jun-Ichi ; YAMADA, Yoshinori ; SAIKAWA, Yoshiro ; OTANI, Yoshihide ; WATANABE, Masahiko ; KUMAI, Koichiro ; KITAJIMA, Masaki ; WATANABE, Jun-Ichi</creator><creatorcontrib>HASHIGUCHI, Naoko ; KUBOTA, Tetsuro ; KOBAYASHI, Motohiro ; KOH, Jun-Ichi ; YAMADA, Yoshinori ; SAIKAWA, Yoshiro ; OTANI, Yoshihide ; WATANABE, Masahiko ; KUMAI, Koichiro ; KITAJIMA, Masaki ; WATANABE, Jun-Ichi</creatorcontrib><description>Background: TZT-1027 is a newly developed antitumor agent derived from dolastatin 10. Materials and Methods: The in vitro
activity of TZT-1027 on MCF-7 and R-27 cells was evaluated by MTT assay. TZT-1027 1 mg/kg/week was administered i.v. for 4
weeks into nude mice bearing MCF-7 and R-27. Subsequently, primary cultured cells from xenografts were also used for CD-DST.
Two mg of TZT-1027 or 40 mg docetaxel per kg were injected i.v. into nude mice bearing R-27. 0.2% Evans blue was injected
to assess the blood flow. Results: TZT-1027 suppressed the in vitro growth of MCF-7 cells, while R-27 cells were resistant
to TZT-1027, although its in vivo antitumor activity was remarkable. TZT-1027 blockaded R-27 tumor blood flow immediately
after injection; blood flow was not affected by docetaxel. Conclusion: TZT-1027 exerts its antitumor activity through direct
cytotoxicity against MCF-7 cells and through selective blockade of tumor blood flow against R-27 cells.</description><identifier>ISSN: 0250-7005</identifier><identifier>EISSN: 1791-7530</identifier><identifier>PMID: 15330161</identifier><language>eng</language><publisher>Attiki: International Institute of Anticancer Research</publisher><subject>Animals ; Antineoplastic Agents - pharmacology ; Biological and medical sciences ; Breast Neoplasms - blood supply ; Breast Neoplasms - drug therapy ; Cell Line, Tumor ; Dose-Response Relationship, Drug ; Female ; Gynecology. Andrology. Obstetrics ; Humans ; Mammary gland diseases ; Medical sciences ; Mice ; Mice, Inbred BALB C ; Mice, Nude ; Neoplasms, Hormone-Dependent - blood supply ; Neoplasms, Hormone-Dependent - drug therapy ; Neovascularization, Pathologic - drug therapy ; Oligopeptides - pharmacology ; Taxoids - pharmacology ; Tumors ; Xenograft Model Antitumor Assays</subject><ispartof>Anticancer research, 2004-07, Vol.24 (4), p.2201-2208</ispartof><rights>2004 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15987881$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15330161$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>HASHIGUCHI, Naoko</creatorcontrib><creatorcontrib>KUBOTA, Tetsuro</creatorcontrib><creatorcontrib>KOBAYASHI, Motohiro</creatorcontrib><creatorcontrib>KOH, Jun-Ichi</creatorcontrib><creatorcontrib>YAMADA, Yoshinori</creatorcontrib><creatorcontrib>SAIKAWA, Yoshiro</creatorcontrib><creatorcontrib>OTANI, Yoshihide</creatorcontrib><creatorcontrib>WATANABE, Masahiko</creatorcontrib><creatorcontrib>KUMAI, Koichiro</creatorcontrib><creatorcontrib>KITAJIMA, Masaki</creatorcontrib><creatorcontrib>WATANABE, Jun-Ichi</creatorcontrib><title>TZT-1027 Elucidates Antitumor Activity through Direct Cytotoxicity and Selective Blockade of Blood Supply</title><title>Anticancer research</title><addtitle>Anticancer Res</addtitle><description>Background: TZT-1027 is a newly developed antitumor agent derived from dolastatin 10. Materials and Methods: The in vitro
activity of TZT-1027 on MCF-7 and R-27 cells was evaluated by MTT assay. TZT-1027 1 mg/kg/week was administered i.v. for 4
weeks into nude mice bearing MCF-7 and R-27. Subsequently, primary cultured cells from xenografts were also used for CD-DST.
Two mg of TZT-1027 or 40 mg docetaxel per kg were injected i.v. into nude mice bearing R-27. 0.2% Evans blue was injected
to assess the blood flow. Results: TZT-1027 suppressed the in vitro growth of MCF-7 cells, while R-27 cells were resistant
to TZT-1027, although its in vivo antitumor activity was remarkable. TZT-1027 blockaded R-27 tumor blood flow immediately
after injection; blood flow was not affected by docetaxel. Conclusion: TZT-1027 exerts its antitumor activity through direct
cytotoxicity against MCF-7 cells and through selective blockade of tumor blood flow against R-27 cells.</description><subject>Animals</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Biological and medical sciences</subject><subject>Breast Neoplasms - blood supply</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Cell Line, Tumor</subject><subject>Dose-Response Relationship, Drug</subject><subject>Female</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>Mammary gland diseases</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Mice, Inbred BALB C</subject><subject>Mice, Nude</subject><subject>Neoplasms, Hormone-Dependent - blood supply</subject><subject>Neoplasms, Hormone-Dependent - drug therapy</subject><subject>Neovascularization, Pathologic - drug therapy</subject><subject>Oligopeptides - pharmacology</subject><subject>Taxoids - pharmacology</subject><subject>Tumors</subject><subject>Xenograft Model Antitumor Assays</subject><issn>0250-7005</issn><issn>1791-7530</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><recordid>eNpN0L1OwzAUBWALgWgpvALyAlukazuxk7GUX6kSA2VhiRzHaQxOHGIHyNuTiiJ1ulc6n85wjtCciIxEImFwjOZAE4gEQDJDZ96_A3CepewUzUjCGBBO5shs3jYRASrwnR2UKWXQHi_bYMLQuB4vVTBfJow41L0btjW-Nb1WAa_G4IL7MWqXybbEL9rqndX4xjr1IUuNXbX73ZQNXWfHc3RSSev1xf4u0Ov93Wb1GK2fH55Wy3VUUy5CRJUmUqiiIiJmBSl5XMmMQiVFASkRVJKEi5JCligCgqeaa1mUUAjKIS3igi3Q9V9v17vPQfuQN8Yrba1stRt8znlKARiZ4OUeDkWjy7zrTSP7Mf8fZwJXeyC9krbqZauMP3BZKtL0wNVmW39PA-W-kdZOtSyXPY3zOKcUCPsFJtl61Q</recordid><startdate>20040701</startdate><enddate>20040701</enddate><creator>HASHIGUCHI, Naoko</creator><creator>KUBOTA, Tetsuro</creator><creator>KOBAYASHI, Motohiro</creator><creator>KOH, Jun-Ichi</creator><creator>YAMADA, Yoshinori</creator><creator>SAIKAWA, Yoshiro</creator><creator>OTANI, Yoshihide</creator><creator>WATANABE, Masahiko</creator><creator>KUMAI, Koichiro</creator><creator>KITAJIMA, Masaki</creator><creator>WATANABE, Jun-Ichi</creator><general>International Institute of Anticancer Research</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>20040701</creationdate><title>TZT-1027 Elucidates Antitumor Activity through Direct Cytotoxicity and Selective Blockade of Blood Supply</title><author>HASHIGUCHI, Naoko ; KUBOTA, Tetsuro ; KOBAYASHI, Motohiro ; KOH, Jun-Ichi ; YAMADA, Yoshinori ; SAIKAWA, Yoshiro ; OTANI, Yoshihide ; WATANABE, Masahiko ; KUMAI, Koichiro ; KITAJIMA, Masaki ; WATANABE, Jun-Ichi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-h267t-2ce1a7cbf1743b1d64fa920fa7b08172a1567d2095c10768e6eabd0b72608b4b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Animals</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Biological and medical sciences</topic><topic>Breast Neoplasms - blood supply</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Cell Line, Tumor</topic><topic>Dose-Response Relationship, Drug</topic><topic>Female</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>Mammary gland diseases</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Mice, Inbred BALB C</topic><topic>Mice, Nude</topic><topic>Neoplasms, Hormone-Dependent - blood supply</topic><topic>Neoplasms, Hormone-Dependent - drug therapy</topic><topic>Neovascularization, Pathologic - drug therapy</topic><topic>Oligopeptides - pharmacology</topic><topic>Taxoids - pharmacology</topic><topic>Tumors</topic><topic>Xenograft Model Antitumor Assays</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>HASHIGUCHI, Naoko</creatorcontrib><creatorcontrib>KUBOTA, Tetsuro</creatorcontrib><creatorcontrib>KOBAYASHI, Motohiro</creatorcontrib><creatorcontrib>KOH, Jun-Ichi</creatorcontrib><creatorcontrib>YAMADA, Yoshinori</creatorcontrib><creatorcontrib>SAIKAWA, Yoshiro</creatorcontrib><creatorcontrib>OTANI, Yoshihide</creatorcontrib><creatorcontrib>WATANABE, Masahiko</creatorcontrib><creatorcontrib>KUMAI, Koichiro</creatorcontrib><creatorcontrib>KITAJIMA, Masaki</creatorcontrib><creatorcontrib>WATANABE, Jun-Ichi</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Anticancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>HASHIGUCHI, Naoko</au><au>KUBOTA, Tetsuro</au><au>KOBAYASHI, Motohiro</au><au>KOH, Jun-Ichi</au><au>YAMADA, Yoshinori</au><au>SAIKAWA, Yoshiro</au><au>OTANI, Yoshihide</au><au>WATANABE, Masahiko</au><au>KUMAI, Koichiro</au><au>KITAJIMA, Masaki</au><au>WATANABE, Jun-Ichi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>TZT-1027 Elucidates Antitumor Activity through Direct Cytotoxicity and Selective Blockade of Blood Supply</atitle><jtitle>Anticancer research</jtitle><addtitle>Anticancer Res</addtitle><date>2004-07-01</date><risdate>2004</risdate><volume>24</volume><issue>4</issue><spage>2201</spage><epage>2208</epage><pages>2201-2208</pages><issn>0250-7005</issn><eissn>1791-7530</eissn><abstract>Background: TZT-1027 is a newly developed antitumor agent derived from dolastatin 10. Materials and Methods: The in vitro
activity of TZT-1027 on MCF-7 and R-27 cells was evaluated by MTT assay. TZT-1027 1 mg/kg/week was administered i.v. for 4
weeks into nude mice bearing MCF-7 and R-27. Subsequently, primary cultured cells from xenografts were also used for CD-DST.
Two mg of TZT-1027 or 40 mg docetaxel per kg were injected i.v. into nude mice bearing R-27. 0.2% Evans blue was injected
to assess the blood flow. Results: TZT-1027 suppressed the in vitro growth of MCF-7 cells, while R-27 cells were resistant
to TZT-1027, although its in vivo antitumor activity was remarkable. TZT-1027 blockaded R-27 tumor blood flow immediately
after injection; blood flow was not affected by docetaxel. Conclusion: TZT-1027 exerts its antitumor activity through direct
cytotoxicity against MCF-7 cells and through selective blockade of tumor blood flow against R-27 cells.</abstract><cop>Attiki</cop><pub>International Institute of Anticancer Research</pub><pmid>15330161</pmid><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0250-7005 |
| ispartof | Anticancer research, 2004-07, Vol.24 (4), p.2201-2208 |
| issn | 0250-7005 1791-7530 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_66820031 |
| source | Free E-Journal (出版社公開部分のみ） |
| subjects | Animals Antineoplastic Agents - pharmacology Biological and medical sciences Breast Neoplasms - blood supply Breast Neoplasms - drug therapy Cell Line, Tumor Dose-Response Relationship, Drug Female Gynecology. Andrology. Obstetrics Humans Mammary gland diseases Medical sciences Mice Mice, Inbred BALB C Mice, Nude Neoplasms, Hormone-Dependent - blood supply Neoplasms, Hormone-Dependent - drug therapy Neovascularization, Pathologic - drug therapy Oligopeptides - pharmacology Taxoids - pharmacology Tumors Xenograft Model Antitumor Assays |
| title | TZT-1027 Elucidates Antitumor Activity through Direct Cytotoxicity and Selective Blockade of Blood Supply |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T09%3A05%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=TZT-1027%20Elucidates%20Antitumor%20Activity%20through%20Direct%20Cytotoxicity%20and%20Selective%20Blockade%20of%20Blood%20Supply&rft.jtitle=Anticancer%20research&rft.au=HASHIGUCHI,%20Naoko&rft.date=2004-07-01&rft.volume=24&rft.issue=4&rft.spage=2201&rft.epage=2208&rft.pages=2201-2208&rft.issn=0250-7005&rft.eissn=1791-7530&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E66820031%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-h267t-2ce1a7cbf1743b1d64fa920fa7b08172a1567d2095c10768e6eabd0b72608b4b3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=66820031&rft_id=info:pmid/15330161&rfr_iscdi=true |